Skip To Main Content
Montalban Xavier on Muck Rack

Montalban Xavier

As seen in: The New England Journal of Medicine
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Montalban

Contact Montalban, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

|
By M. D. Bar-Or. Amit, M. D. Giovannoni. Gavin, M. D. Hartung. Hans-Peter, M. D. Hemmer. Bernhard, M. D. Lublin. Fred, Montalban Xavier, M. D. Hauser. Stephen L, M. D. Kappos. Ludwig, M. D. de. Seze Jérôme, M. D. Rammohan. Kottil
| The New England Journal of Medicine Verified
In this phase 3 trial, we randomly assigned 732 patients with primary progressive multiple sclerosis in a 2:1 ratio to receive intravenous ocrelizumab (600 mg) or placebo every 24 weeks for at least 120 weeks and until a prespecified number of confirmed disability progression events had occurred. The primary end point was the percentage of patients with disability progression confirmed at 12 weeks in a time-to-event analysis.
Open in Who Shared Issue with article?
See all 1 articles